Skip to main content
NCBI home page
The Yale Journal of Biology and Medicine logoLink to The Yale Journal of Biology and Medicine
. 1989 Nov-Dec;62(6):653–664.

Effect of extracorporeal photopheresis on selected immunologic parameters in psoriasis vulgaris.

E C Vonderheid 1, R D Bigler 1, T J Rogers 1, M E Kadin 1, T D Griffin 1
PMCID: PMC2589147  PMID: 2636805

Abstract

Extracorporeal photopheresis (ExP) was administered every other week in an outpatient setting to four patients with chronic refractory psoriasis vulgaris without arthropathy. The duration of treatment ranged from six to 13 months. Two patients received methotrexate concomitantly during the initial phase of the study. All patients demonstrated a decrease in erythema, induration, and scaling of lesional skin, accompanied by incomplete clearing of lesions such that the percentage of involvement (SI) ranged between 40 to 80 percent of baseline scores. Exacerbations of psoriasis occurred with minor provocations, and two patients who were predisposed to developing epithelial skin neoplasms as a consequence of prior treatments continued to develop tumors during the study interval. Prolonged ExP treatment was otherwise well tolerated, without evidence of toxicity on routine laboratory safety tests or changes in lymphocyte counts. All patients, however, exhibited decreased intradermal skin responses to recall antigens and a decreased capacity of peripheral lymphocytes to produce interleukin 2 (IL-2) in response to polyclonal stimuli in vitro. These observations suggest that the observed anti-inflammatory effect of alternate-week ExP on psoriasis is mediated in part to a direct inhibition of lymphokine production or release by psoralen-ultraviolet-exposed lymphocytes.

Full text

PDF
653

Images in this article

658FIG. 1
on p.658
658FIG. 2
on p.658

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Auböck J., Romani N., Grubauer G., Fritsch P. HLA-DR expression on keratinocytes is a common feature of diseased skin. Br J Dermatol. 1986 Apr;114(4):465–472. doi: 10.1111/j.1365-2133.1986.tb02851.x. [DOI] [PubMed] [Google Scholar]
  2. Baker B. S., Swain A. F., Fry L., Valdimarsson H. Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br J Dermatol. 1984 May;110(5):555–564. doi: 10.1111/j.1365-2133.1984.tb04678.x. [DOI] [PubMed] [Google Scholar]
  3. Baker B. S., Swain A. F., Valdimarsson H., Fry L. T-cell subpopulations in the blood and skin of patients with psoriasis. Br J Dermatol. 1984 Jan;110(1):37–44. doi: 10.1111/j.1365-2133.1984.tb07309.x. [DOI] [PubMed] [Google Scholar]
  4. Bjerke J. R., Matre R. Demonstration of Ia-like antigens on T lymphocytes in lesions of psoriasis, lichen planus and discoid lupus erythematosus. Acta Derm Venereol. 1983;63(2):103–107. [PubMed] [Google Scholar]
  5. Bjerke J. R. Subpopulations of mononuclear cells in lesions of psoriasis, lichen planus and discoid lupus erythematosus studied using monoclonal antibodies. Acta Derm Venereol. 1982;62(6):477–483. [PubMed] [Google Scholar]
  6. Bos J. D., Hulsebosch H. J., Krieg S. R., Bakker P. M., Cormane R. H. Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res. 1983;275(3):181–189. doi: 10.1007/BF00510050. [DOI] [PubMed] [Google Scholar]
  7. Bos J. D. The pathomechanisms of psoriasis; the skin immune system and cyclosporin. Br J Dermatol. 1988 Feb;118(2):141–155. doi: 10.1111/j.1365-2133.1988.tb01768.x. [DOI] [PubMed] [Google Scholar]
  8. Bos J. D., van Garderen I. D., Krieg S. R., Poulter L. W. Different in situ distribution patterns of dendritic cells having Langerhans (T6+) and interdigitating (RFD1+) cell immunophenotype in psoriasis, atopic dermatitis, and other inflammatory dermatoses. J Invest Dermatol. 1986 Sep;87(3):358–361. doi: 10.1111/1523-1747.ep12524811. [DOI] [PubMed] [Google Scholar]
  9. Bunjes D., Hardt C., Röllinghoff M., Wagner H. Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2. Eur J Immunol. 1981 Aug;11(8):657–661. doi: 10.1002/eji.1830110812. [DOI] [PubMed] [Google Scholar]
  10. Camp R. D., Fincham N. J., Cunningham F. M., Greaves M. W., Morris J., Chu A. Psoriatic skin lesions contain biologically active amounts of an interleukin 1-like compound. J Immunol. 1986 Dec 1;137(11):3469–3474. [PubMed] [Google Scholar]
  11. Czernielewski J. M., Bagot M. Class II MHC antigen expression by human keratinocytes results from lympho-epidermal interactions and gamma-interferon production. Clin Exp Immunol. 1986 Nov;66(2):295–302. [PMC free article] [PubMed] [Google Scholar]
  12. Edelson R. L. Light-activated drugs. Sci Am. 1988 Aug;259(2):68–75. doi: 10.1038/scientificamerican0888-68. [DOI] [PubMed] [Google Scholar]
  13. Edelson R., Berger C., Gasparro F., Jegasothy B., Heald P., Wintroub B., Vonderheid E., Knobler R., Wolff K., Plewig G. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med. 1987 Feb 5;316(6):297–303. doi: 10.1056/NEJM198702053160603. [DOI] [PubMed] [Google Scholar]
  14. Ellis C. N., Gorsulowsky D. C., Hamilton T. A., Billings J. K., Brown M. D., Headington J. T., Cooper K. D., Baadsgaard O., Duell E. A., Annesley T. M. Cyclosporine improves psoriasis in a double-blind study. JAMA. 1986 Dec 12;256(22):3110–3116. [PubMed] [Google Scholar]
  15. Fredriksson T., Pettersson U. Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978;157(4):238–244. doi: 10.1159/000250839. [DOI] [PubMed] [Google Scholar]
  16. Gillis S., Ferm M. M., Ou W., Smith K. A. T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol. 1978 Jun;120(6):2027–2032. [PubMed] [Google Scholar]
  17. Gottlieb A. B. Immunologic mechanisms in psoriasis. J Am Acad Dermatol. 1988 Jun;18(6):1376–1380. doi: 10.1016/s0190-9622(88)70145-0. [DOI] [PubMed] [Google Scholar]
  18. Griffin T. D., Lattanand A., VanScott E. J. Clinical and histologic heterogeneity of psoriatic plaques. Therapeutic relevance. Arch Dermatol. 1988 Feb;124(2):216–220. [PubMed] [Google Scholar]
  19. Kadin M., Nasu K., Sako D., Said J., Vonderheid E. Lymphomatoid papulosis. A cutaneous proliferation of activated helper T cells expressing Hodgkin's disease-associated antigens. Am J Pathol. 1985 May;119(2):315–325. [PMC free article] [PubMed] [Google Scholar]
  20. Kaudewitz P., Braun-Falco O., Kind P., Galosi A., Rieber P., Riethmüller G. Distribution of T-cell subsets as defined by monoclonal antibodies in skin lesions of psoriasis vulgaris. Arch Dermatol Res. 1984;276(1):33–35. doi: 10.1007/BF00412559. [DOI] [PubMed] [Google Scholar]
  21. Kupper T. S., Ballard D. W., Chua A. O., McGuire J. S., Flood P. M., Horowitz M. C., Langdon R., Lightfoot L., Gubler U. Human keratinocytes contain mRNA indistinguishable from monocyte interleukin 1 alpha and beta mRNA. Keratinocyte epidermal cell-derived thymocyte-activating factor is identical to interleukin 1. J Exp Med. 1986 Dec 1;164(6):2095–2100. doi: 10.1084/jem.164.6.2095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Lee R. E., Gaspari A. A., Lotze M. T., Chang A. E., Rosenberg S. A. Interleukin 2 and psoriasis. Arch Dermatol. 1988 Dec;124(12):1811–1815. [PubMed] [Google Scholar]
  23. Luger T. A., Stadler B. M., Katz S. I., Oppenheim J. J. Epidermal cell (keratinocyte)-derived thymocyte-activating factor (ETAF). J Immunol. 1981 Oct;127(4):1493–1498. [PubMed] [Google Scholar]
  24. Morhenn V. B., Abel E. A., Mahrle G. Expression of HLA-DR antigen in skin from patients with psoriasis. J Invest Dermatol. 1982 Feb;78(2):165–168. doi: 10.1111/1523-1747.ep12506332. [DOI] [PubMed] [Google Scholar]
  25. Muramoto L. M., Kadin M. E. Improved detection of lymphoid cell surface antigens in tissues fixed in periodate-lysine-paraformaldehyde (PLP). Am J Clin Pathol. 1987 Nov;88(5):589–595. doi: 10.1093/ajcp/88.5.589. [DOI] [PubMed] [Google Scholar]
  26. Nasu K., Said J., Vonderheid E., Olerud J., Sako D., Kadin M. Immunopathology of cutaneous T-cell lymphomas. Am J Pathol. 1985 Jun;119(3):436–447. [PMC free article] [PubMed] [Google Scholar]
  27. Nickoloff B. J., Basham T. Y., Merigan T. C., Morhenn V. B. Keratinocyte class II histocompatibility antigen expression. Br J Dermatol. 1985 Mar;112(3):373–374. doi: 10.1111/j.1365-2133.1985.tb04868.x. [DOI] [PubMed] [Google Scholar]
  28. Ragaz A., Ackerman A. B. Evolution, maturation, and regression of lesions of psoriasis. New observations and correlation of clinical and histologic findings. Am J Dermatopathol. 1979 Fall;1(3):199–214. doi: 10.1097/00000372-197900130-00002. [DOI] [PubMed] [Google Scholar]
  29. Romero L. I., Ikejima T., Pincus S. H. In situ localization of interleukin-1 in normal and psoriatic skin. J Invest Dermatol. 1989 Oct;93(4):518–522. doi: 10.1111/1523-1747.ep12284068. [DOI] [PubMed] [Google Scholar]
  30. Sauder D. N. Interleukin 1. Arch Dermatol. 1989 May;125(5):679–682. [PubMed] [Google Scholar]
  31. Wentzell J. M., Baughman R. D., O'Connor G. T., Bernier G. M., Jr Cyclosporine in the treatment of psoriasis. Arch Dermatol. 1987 Feb;123(2):163–165. [PubMed] [Google Scholar]
  32. de Panfilis G., Allegra F. Immunohistochemical study of dermal cell popoulation in psoriatic skin. Acta Derm Venereol Suppl (Stockh) 1979;87:22–26. [PubMed] [Google Scholar]

Articles from The Yale Journal of Biology and Medicine are provided here courtesy of Yale Journal of Biology and Medicine

RESOURCES